Klotho Neurosciences, Inc. (KLTO)
Automate Your Wheel Strategy on KLTO
With Tiblio's Option Bot, you can configure your own wheel strategy including KLTO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KLTO
- Rev/Share 0.0
- Book/Share 0.3137
- PB 1.972
- Debt/Equity 0.0
- CurrentRatio 135.7379
- ROIC -0.7607
- MktCap 32602138.0
- FreeCF/Share -0.1631
- PFCF -5.8856
- PE -1.8498
- Debt/Assets 0.0
- DivYield 0
- ROE -3.2591
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
Published: September 30, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK and PALO ALTO, Calif. , Sept. 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho" or "the Company") today announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. ("Turn"), a leader in induced pluripotent stem cells (iPSC) and cellular reprogramming.
Read More
Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
Published: August 18, 2025 by: PRNewsWire
Sentiment: Neutral
Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the development of Klotho-based therapeutics NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, provides a strategic update to shareholders highlighting the Company's key milestones and pipeline progress. These achievements strengthen Klotho's position as it advances toward the large and growing market for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and Parkinson's disease therapies, which is estimated at over $8 billion annually by Grand View Research and others.
Read More
Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Published: July 24, 2025 by: PRNewsWire
Sentiment: Neutral
Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK , July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced today that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform.
Read More
Klotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy Assets
Published: July 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , July 22, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), announced that it is partnering with AAVnerGene Inc. (AAVnerGene), a Rockville, MD-based innovation-driven biotech renowned for its transformative technologies in AAV manufacturing and tissue-targeted delivery. Dr. Joseph Sinkule, the CEO of KLTO stated "we announced previously that we have been looking for a more efficient, 'next-generation' method to manufacture several of our patented gene therapy candidates, and the two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to …
Read More
Klotho Neurosciences' ALS therapy awarded FDA Orphan Drug Designation
Published: July 10, 2025 by: Proactive Investors
Sentiment: Positive
Klotho Neurosciences (NASDAQ:KLTOW) announced that its novel therapy KLTO-202, also known as s-KL-AAV.myo, for the treatment of Amyotrophic Lateral Sclerosis (ALS) has received Orphan Drug Designation from the US Food and Drug Administration (FDA), The news sent Klotho's shares higher in early trade on Thursday, up 5.8% at about $1.45. ALS is a rare, progressive neurodegenerative disease commonly known as Lou Gehrig's disease.
Read More
About Klotho Neurosciences, Inc. (KLTO)
- IPO Date 2022-04-29
- Website https://klothoneuro.com
- Industry Biotechnology
- CEO Joseph Sinkule
- Employees 3